Cantor Fitzgerald Starts Valeant Pharmaceuticals (VRX) at Buy
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Cantor Fitzgerald initiated coverage on Valeant Pharmaceuticals (NYSE: VRX) with a Buy rating and a price target of $200.00.
Analyst Irina Rivkind Kofflers said, "We found it difficult to poke holes in this business model, which avoids the majority of traditional pharmaceutical risk while uniting the most attractive elements of successful predecessor companies under a single roof. We appreciate Valeant's cash pay verticals (dermatology/aesthetic medicine, ophthalmology, and dental health), diversified portfolio, selective international expansion into areas with high healthcare spending, high operating margins, low tax, and focused management team."
"We also like the company's relatively disciplined and transparent approach to M&A as well as a demonstrated track record of successful deal integration. We therefore expect the business to remain on a healthy double-digit growth trajectory via more tuck-in acquisitions, selective SG&A investment, and continued expense management, and see the stock as undervalued both fundamentally and on a comparables basis," added the analyst.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $129.07 yesterday.
Analyst Irina Rivkind Kofflers said, "We found it difficult to poke holes in this business model, which avoids the majority of traditional pharmaceutical risk while uniting the most attractive elements of successful predecessor companies under a single roof. We appreciate Valeant's cash pay verticals (dermatology/aesthetic medicine, ophthalmology, and dental health), diversified portfolio, selective international expansion into areas with high healthcare spending, high operating margins, low tax, and focused management team."
"We also like the company's relatively disciplined and transparent approach to M&A as well as a demonstrated track record of successful deal integration. We therefore expect the business to remain on a healthy double-digit growth trajectory via more tuck-in acquisitions, selective SG&A investment, and continued expense management, and see the stock as undervalued both fundamentally and on a comparables basis," added the analyst.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $129.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Resumes EQT Corp. (EQT) at Hold
- B.Riley Resumes Magnite (MGNI) at Buy
- Loop Capital Starts Instacart (CART) at Buy, 'Leading a Massive and Underpenetrated Category'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot New Coverage, New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
